Rallybio/$RLYB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rallybio
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Ticker
$RLYB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
24
Website
Rallybio Metrics
BasicAdvanced
$19M
-
-$1.08
-1.17
-
Price and volume
Market cap
$19M
Beta
-1.17
52-week high
$1.41
52-week low
$0.22
Average daily volume
5.6M
Financial strength
Current ratio
14.675
Quick ratio
13.937
Total debt to equity
0.215
Profitability
EBITDA (TTM)
-50.255
Gross margin (TTM)
-3,944.34%
Net profit margin (TTM)
-5,682.19%
Operating margin (TTM)
-5,940.92%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-40.02%
Return on equity (TTM)
-67.28%
Valuation
Price to revenue (TTM)
24.427
Price to book
0.36
Price to tangible book (TTM)
0.36
Price to free cash flow (TTM)
-0.47
Free cash flow yield (TTM)
-212.57%
Free cash flow per share (TTM)
-0.988
Growth
Earnings per share change (TTM)
-42.45%
3-year earnings per share growth (CAGR)
-14.84%
What the Analysts think about Rallybio
Analyst ratings (Buy, Hold, Sell) for Rallybio stock.
Rallybio Financial Performance
Revenues and expenses
Rallybio Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rallybio stock?
Rallybio (RLYB) has a market cap of $19M as of August 01, 2025.
What is the P/E ratio for Rallybio stock?
The price to earnings (P/E) ratio for Rallybio (RLYB) stock is 0 as of August 01, 2025.
Does Rallybio stock pay dividends?
No, Rallybio (RLYB) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Rallybio dividend payment date?
Rallybio (RLYB) stock does not pay dividends to its shareholders.
What is the beta indicator for Rallybio?
Rallybio (RLYB) has a beta rating of -1.17. This means that it has an inverse relation to market volatility.